Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
8.44
+1.28 (17.88%)
Feb 21, 2025, 4:00 PM EST - Market closed
Avalo Therapeutics Employees
Avalo Therapeutics had 19 employees as of December 31, 2023. The number of employees decreased by 1 or -5.00% compared to the previous year.
Employees
19
Change (1Y)
-1
Growth (1Y)
-5.00%
Revenue / Employee
$43,158
Profits / Employee
-$428,158
Market Cap
88.31M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
AVTX News
- 18 days ago - Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 7 weeks ago - Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer - GlobeNewsWire
- 3 months ago - Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants - GlobeNewsWire
- 3 months ago - Avalo Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa - GlobeNewsWire
- 7 months ago - Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer - GlobeNewsWire
- 8 months ago - Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa - GlobeNewsWire
- 8 months ago - Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer - GlobeNewsWire